Methods and compositions for delivering interleukin-1 receptor antagonist
View Patent ↗Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.
1. A method for generating a solution rich in interleukin-1 receptor antagonist, comprising contacting a liquid volume comprising white blood cells with a concentrating material, the liquid volume having a concentration of white blood cells at least equal to the concentration of white blood cells in whole blood.
2. The method of claim 1 , wherein the liquid volume comprises whole blood, platelet-rich plasma, bone marrow aspirate, a bone marrow concentrate, a white blood cell fraction, a buffy coat fraction, a white blood cell isolate, or a combination thereof.
3. The method of claim 1 , wherein the contacting includes incubating the liquid volume with the concentrating material for a period of time from about 30 seconds to about 24 hours.
4. The method of claim 1 , wherein the concentrating material comprises a porous material, an absorptive material, a desiccating material, a filter, or a combination thereof.
5. The method of claim 1 , wherein the concentrating material comprises polyacrylamide beads.
6. The method of claim 1 , wherein the contacting generates a solution having an interleukin-1 receptor antagonist concentration of at least about 10,000 pg/ml.
7. The method of claim 1 , wherein the solution comprises soluble tumor necrosis factor receptor 1 (sTNF-R1) at a concentration greater than the concentration of the sTNF-R1 present in whole blood or plasma.
8. A method of making a solution rich in interleukin-1 receptor antagonist, comprising contacting a liquid volume of white blood cells with a solid activator configured to activate white blood cells to generate interleukin-1 receptor antagonist, the liquid volume having a concentration of white blood cells greater than or equal to a concentration of white blood cells in whole blood.
9. The method of claim 6 , wherein the solution has a concentration of interleukin-1 receptor antagonist of at least about 30,000 pg/ml.
10. The method of claim 6 , wherein the solid activator comprises a porous material, a desiccating material, an absorptive material, a filter, or a combination thereof.
11. The method of claim 6 , wherein the solid activator comprises polyacrylamide beads.
12. The method of claim 6 , wherein the liquid volume comprises a platelet-rich plasma, a bone marrow aspirate, a bone marrow concentrate, a white blood cell fraction, a buffy coat fraction, a white blood cell isolate, or a combination thereof.
13. The method of claim 6 , wherein the contacting comprises incubating the liquid volume with the solid activator for a period of time from about 30 seconds to about 24 hours.